News from provention bio, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Apr 08, 2021, 16:01 ET Provention Bio Provides Regulatory Update on Biologics License Application for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-Risk Individuals

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced...

Mar 04, 2021, 07:30 ET Provention Bio to Present at Two Upcoming Virtual Investor Conferences

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced...

Mar 03, 2021, 16:01 ET Provention Bio Announces Publication of Extended Follow-up Data from the Pivotal "At-Risk" TN-10 Study of Teplizumab in Science Translational Medicine

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced...

Feb 25, 2021, 07:00 ET Provention Bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported...

Feb 18, 2021, 07:30 ET Provention Bio to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced...

Feb 17, 2021, 16:00 ET Provention Bio and Huadong Announce Strategic Collaboration to Develop and Commercialize PRV-3279 in Greater China

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, and Hangzhou...

Jan 28, 2021, 07:30 ET Provention Bio Announces Key Findings from Pre-clinical Proof-of-concept Study for PRV-3279 for the Prevention of Immunogenicity of Gene Therapy

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reported...

Jan 13, 2021, 19:03 ET Provention Bio Announces Pricing of $100 Million Public Offering of Common Stock

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced...

Jan 12, 2021, 16:26 ET Provention Bio Announces Proposed Public Offering of Common Stock

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced...

Jan 06, 2021, 16:05 ET Provention Bio to Participate in the H.C. Wainwright Virtual BioConnect Conference

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced...

Jan 04, 2021, 07:00 ET Provention Bio Announces U.S. FDA Filing of a Biologics License Application (BLA) and Priority Review for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-risk Individuals

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced...

Dec 21, 2020, 07:30 ET Provention Bio Announces Addition to NASDAQ Biotechnology Index

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced...

Dec 15, 2020, 07:30 ET Provention Bio Initiates First-in-Human Study of Coxsackievirus B Vaccine Candidate PRV-101

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced...

Nov 11, 2020, 07:30 ET Provention Bio to Present at the Stifel Virtual Healthcare Conference

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today announced that...

Nov 05, 2020, 07:00 ET Provention Bio Reports Third Quarter 2020 Financial Results and Provides Business Update

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today reported...

Nov 02, 2020, 07:30 ET Provention Bio Completes Rolling Submission of the Biologics License Application (BLA) for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-risk Individuals

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today announced the...

Oct 29, 2020, 07:30 ET Provention Bio to Report Third Quarter 2020 Financial Results and Host Conference Call on Thursday, November 5, 2020

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today announced that it ...

Oct 01, 2020, 07:30 ET Provention Bio Announces National Effort to Redefine Patient Care in Type 1 Diabetes (T1D)

Provention Bio, Inc. (Nasdaq:PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, yesterday launched a...

Sep 30, 2020, 16:05 ET Provention Bio Files Clinical Module for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-Risk Individuals

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced...

Sep 08, 2020, 07:30 ET Provention Bio to Present at Upcoming Virtual Investor Conferences

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced...

Aug 31, 2020, 07:30 ET Provention Bio Announces Initiation of Phase 2b PROACTIVE Study of PRV-015 (anti-IL-15) in Non-responsive Celiac Disease

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced...

Aug 11, 2020, 07:00 ET John K. Jenkins, MD Joins Provention Bio Board of Directors

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced...

Aug 06, 2020, 07:00 ET Provention Bio Reports Second Quarter 2020 Financial Results and Provides Business Update

Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease,...

Aug 03, 2020, 16:05 ET Provention Bio Appoints Heidy Abreu King-Jones as Chief Legal Officer

Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced...

Jul 30, 2020, 07:00 ET Provention Bio to Report Second Quarter 2020 Financial Results and Host Conference Call on Thursday, August 6, 2020

Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease,...